Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2329 - Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC)

Date

11 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Breast Cancer

Presenters

Matthew Wongchenko

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

M. Wongchenko1, R. Dent2, S. Kim3, C. Saura4, M. Oliveira4, J. Baselga5, A.V. Kapp6, W.Y. Chan7, S.M. Singel7, D.J. Maslyar7, S. Gendreau8

Author affiliations

  • 1 Oncology Biomarker Development, Genentech Inc., 9408097124 - South San Francisco/US
  • 2 Division Of Medical Oncology, National Cancer Centre, Singapore/SG
  • 3 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 4 Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 5 Human Oncology And Pathogenesis Program And The Department Of Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 6 Product Development Biostatistics, Genentech Inc., South San Francisco/US
  • 7 Product Development Oncology, Genentech Inc., South San Francisco/US
  • 8 Oncology Biomarker Development, Genentech Inc., South San Francisco/US
More

Resources

Abstract 2329

Background

The oral Akt inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/Akt pathway activation. In the placebo-controlled randomised phase II LOTUS trial (NCT02162719), adding IPAT to P as first-line therapy for metastatic TNBC improved PFS in unselected patients (stratified hazard ratio [HR] 0.60 [90% CI 0.40–0.91]), with a more pronounced effect in patients with PIK3CA/AKT1/PTEN-altered tumours [Dent, ASCO 2017]. cfDNA sequencing was performed to assess the utility of blood samples for detecting tumour mutations in TNBC.

Methods

Pre-treatment plasma and tumour samples were evaluated for genetic alterations using Foundation Medicine’s FoundationACT® and FoundationOne® next-generation sequencing assays, respectively. Samples from 88 patients were evaluable by cfDNA, 72 of whom also had evaluable tumour samples (52 primary tumour). To test the prognostic effect of cfDNA mutational burden, patients were classified as having high or low variant allele fraction (VAF) in cfDNA using the median as a cutoff.

Results

In 81 patients (92%), at least one mutation was detectable by cfDNA sequencing. Concordance with tissue sequencing was 75%. High VAF was associated with shorter PFS than low VAF in both the IPAT + P arm (HR 2.39 [90% CI 1.19–4.70]) and the placebo + P arm (HR 2.68 [90% CI 1.46–5.11]). High VAF was also associated with the presence of > 1 metastatic site but not tumour volume per RECIST v1.1. In 22 patients (25%), an activating PIK3CA (n = 16) or AKT1 (n = 6) mutation was detected in cfDNA; concordance with tissue sequencing was 100%. PFS improvement with the addition of IPAT to P was more pronounced in patients with detectable PIK3CA/AKT1 mutations (HR 0.15 [90% CI 0.03–0.50]) than in those without a detectable mutation (HR 0.82 [90% CI 0.50–1.31]).

Conclusions

These results highlight the potential role of cfDNA in evaluating patient prognosis as well as identifying genetic markers associated with improved treatment outcomes. Furthermore, they support the occurrence of PIK3CA and AKT1 mutations as early genetic events present in primary tissue samples that are maintained during metastasis.

Clinical trial identification

NCT02162719

Legal entity responsible for the study

F Hoffmann-La Roche Ltd.

Funding

F Hoffmann-La Roche Ltd

Disclosure

M. Wongchenko: Employee of Genentech, Inc. and holds shares in Roche and Ariad Pharmaceuticals. R. Dent: Honoraria for consultancy/advisory boards/speaker engagements from Pfizer, Roche, Eisai, Merck, and AstraZeneca. S-B. Kim: Research funding from Novartis, Sanofi-Aventis, Kyowa-Kirin Inc, and Dongkook Pharma Co., Ltd. C. Saura: Honoraria for consulting/advisory roles from Puma Biotechnology, Pfizer, and Roche and research funding (to her institution) from Genentech and AstraZeneca. M. Oliveira: Honoraria for consulting/advisory roles from Puma Biotechnology and Genentech/Roche and research funding (to the institution) from Genentech and AstraZeneca. J. Baselga: Compensation for a leadership role from Infinity Pharmaceuticals, stock or ownership interest in PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, and GRAIL, and honoraria for consulting/advisory role for Eli Lilly, Novartis, and GRAIL. A.V. Kapp, W.Y. Chan, S.M. Singel, D.J. Maslyar, S. Gendreau: Employee of Genentech, Inc. and holds stock in Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.